ArticleJournal of immunology research2016
CD3(+)CD8(+)CD28(-) T Lymphocytes in Patients with Lupus Nephritis.
Article in Journal of immunology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 29 citations in OpenAlex.
- First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects.Clinical and translational science · 2021Trial
- Integrated immune profiling identifies a coordinated T-cell activation and inflammatory signature in SLE.Lupus science & medicine · 2026Article
- T-Cell Immunosenescence in Systemic Lupus Erythematosus: Molecular Mechanisms and Therapeutic Perspectives.Clinical reviews in allergy & immunology · 2026Review
- Prognostic value of BMI, prognostic nutritional index, and CRP in patients with lymphoma after autologous hematopoietic stem cell transplantation.Biomedical engineering online · 2026Article
- Efficacy of Telitacicept in Childhood-Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting-Adjusted Comparison to a Historical Control Group Treated With Belimumab.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- CD8Frontiers in immunology · 2026Review
- Inflammasome activation and accelerated immune aging in autoimmune disorders.Frontiers in aging · 2025Article
- How Co-Stimulatory/Inhibitory Molecules Vary Across Immune Cell Subtypes in the Severity of Systemic Lupus Erythematosus Compared to Controls.Biomedicines · 2024Article
- Article
- Senescent T cells: Beneficial and detrimental roles.Immunological reviews · 2023Review
- Diagnostic Values of METTL1-Related Genes and Immune Characteristics in Systemic Lupus Erythematosus.Journal of inflammation research · 2023Article
- Age-related mechanisms in the context of rheumatic disease.Nature reviews. Rheumatology · 2022Review
- Different Types of Chronic Inflammation Engender Distinctive Immunosenescent Profiles in Affected Patients.International journal of molecular sciences · 2022Article
- Excessive IL-15 promotes cytotoxic CD4 + CD28- T cell-mediated renal injury in lupus nephritis.Immunity & ageing : I & A · 2022Article
- Effect of panel reactive antibodies on T cell immunity reinstatement following renal transplantation.World journal of transplantation · 2022Article
- CD8International journal of molecular sciences · 2022Review
- Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models.Arthritis research & therapy · 2022Article
- CD8+ T-Cells in Juvenile-Onset SLE: From Pathogenesis to Comorbidities.Frontiers in medicine · 2022Review
- Harnessing CD8Cells · 2021Review
- Mass Cytometry Analysis Reveals that Specific Intratumoral CD4Cell reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The results of studies on the CD3(+)CD8(+)CD28(-) cells in SLE are inconsistent since several analyses describe CD3(+)CD8(+)CD28(-) as either immunosuppressive or cytotoxic. The aim of this study is to inquire whether the quantitative changes of CD3(+)CD8(+)CD28(-) T lymphocytes subpopulation are related to the clinical status of patients with lupus nephritis. Evaluation of Foxp3 expression on CD3(+)CD8(+)CD28(-) cells may shed some light on functional properties of these cells. 54 adult SLE patients and 19 sex and age matched healthy volunteers were enrolled in the study. There were 15 patients in inactive (SLEDAI ≤ 5) and 39 in active (SLEDAI > 5) phase of disease. We determined absolute count of CD3(+)CD8(+)CD28(-) and CD3(+)CD8(+)CD28(-)Foxp3(+) subpopulations by flow cytometry. We observed a statistically significant increase in absolute count and percentage of CD3(+)CD8(+)CD28(-) in SLE patients compared to HC (p < 0.001). Moreover there was significant positive correlation between increasing absolute count of CD3(+)CD8(+)CD28(-) cells and disease activity measured by SLEDAI (rs = 0.281, p = 0.038). Active LN patients had increased absolute count of CD3(+)CD8(+)CD28(-) cells compared to HC. Positive correlation of CD3(+)CD8(+)CD28(-) number with disease activity, and lack of Foxp3 expression on these cells, suggests that CD3(+)CD8(+)CD28(-) lymphocytes might be responsible for an increased proinflammatory response in the exacerbation of SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.